Leading Specialty Pharmaceuticals Business, Kent Pharma, has appointed Terry Petersen as CEO

Terry Petersen has been appointed the new CEO of Kent Pharma, a leading manufacturer and distributor of specialty pharmaceuticals.

Terry brings with him strong leadership experience and a background predominantly in pharmaceuticals, where he has positively designed, started, scaled and led European businesses to successfully commercialise specialty products and other high-value medicines whilst addressing patient needs.

Terry has worked within a broad spectrum of pharmaceutical companies including Daiichi Sankyo, Clinigen Idis Group, Sunovion Pharmaceuticals Europe (renamed CNX Therapeutics), as well as has experience working within private equity-backed businesses.

In 2019, leading mid-market private equity group Duke Street acquired Kent Pharma and have supported the business in growing the portfolio, investing in new product development and internationalising the business in Europe via a strong network of commercial partners.

Commenting on Terry’s appointment, Duke Street’s Investment Director, Renée Hoff said “Terry has an impressive knowledge of our sector and a strong strategic vision, and we are very much looking forward to collaborating with him to deliver on the investment strategy”.

Carter Schwartz’s Head of Practice, Private Equity, Lewis Buckley advised on this appointment.